Glofitamab治疗复发/难治性原发中枢神经系统淋巴瘤的多中心真实世界分析
这项多中心真实世界研究评估了Glofitamab单药治疗16例复发/难治性原发中枢神经系统淋巴瘤成年患者的疗效、中枢神经系统穿透性和分子应答动态。结果显示总缓解率为75%,完全缓解率为50%,中位无进展生存期为15.4个月,中位总生存期未达到。脑脊液中可检测到Glofitamab的患者占60%,早期脑脊液ctDNA清除与影像学缓解相关。
要点
- Glofitamab单药在复发/难治性原发中枢神经系统淋巴瘤中显示早期临床活性,总缓解率75%。
- 脑脊液中可检测到Glofitamab,脑脊液/血浆比值最高达0.44%。
- 早期脑脊液ctDNA清除与影像学缓解相关,持续或再现ctDNA先于临床进展。
核心结论
- Glofitamab在复发/难治性原发中枢神经系统淋巴瘤中显示早期临床活性和可测量的中枢神经系统穿透性。
- 连续脑脊液ctDNA分析可能有助于治疗监测,值得前瞻性验证。
研究设计与样本
- 多中心真实世界研究,纳入16例接受Glofitamab单药治疗的复发/难治性原发中枢神经系统淋巴瘤成年患者。
- 分析配对血浆和脑脊液样本以评估中枢神经系统药物穿透性。
- 在Glofitamab单药治疗期间进行连续脑脊液循环肿瘤DNA分析,并在接受CAR-T巩固治疗的患者中检查CAR-T细胞动力学。
主要发现
- Glofitamab单药治疗的中期总缓解率为75%,包括50%的完全缓解。
- 中位无进展生存期为15.4个月,中位总生存期未达到。
- 60%的患者脑脊液中可检测到Glofitamab,脑脊液/血浆比值最高达0.44%。
- 纵向ctDNA分析显示,早期分子清除与影像学缓解相关,而持续或再现的ctDNA先于临床进展。
- 安全性总体可控,大多数不良事件为1-2级;2例(11%)发生≥3级神经毒性,经糖皮质激素治疗后恢复;另有2例在CAR-T巩固治疗后发生致死性免疫效应细胞相关神经毒性综合征。
临床怎么用
- Glofitamab可作为复发/难治性原发中枢神经系统淋巴瘤的一种治疗选择,部分患者可桥接至CAR-T和/或自体造血干细胞移植。
- 连续脑脊液ctDNA监测可能有助于评估治疗应答和早期识别进展。
- 需警惕神经毒性,包括Glofitamab治疗相关及后续CAR-T巩固治疗后的免疫效应细胞相关神经毒性综合征。
局限性
- 样本量小(16例),为真实世界研究。
- 部分患者后续接受CAR-T和/或自体造血干细胞移植,可能影响长期结局。
- 脑脊液ctDNA监测的临床价值需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Therapeutic options for relapsed/refractory (R/R) primary CNS lymphoma (PCNSL) are limited, and the clinical activity and central nervous system (CNS) pharmacology of CD20 × CD3 bispecific antibody glofitamab remain poorly defined. This multicenter real-world study evaluated the efficacy, CNS penetration, and molecular response dynamics of glofitamab in 16 adults with R/R PCNSL treated with glofitamab monotherapy. Paired plasma and cerebrospinal fluid (CSF) samples were analyzed to assess CNS drug penetration. Serial CSF circulating tumor DNA (ctDNA) profiling was performed during glofitamab monotherapy, and chimeric antigen receptor T (CAR-T) cell kinetics were examined in patients receiving CAR-T consolidation. Glofitamab monotherapy achieved an interim overall response rate of 75%, including 50% complete responses. Median progression-free survival was 15.4 months, and median overall survival was not reached. In several patients, glofitamab was used as a bridge to subsequent CAR-T and/or autologous stem cell transplantation (ASCT), which may have influenced long-term outcomes. Glofitamab was detectable in the CSF of 60% of patients, with CSF/plasma ratios up to 0.44%. Longitudinal ctDNA analysis demonstrated that early molecular clearance was associated with radiographic response, while persistent or re-emergent ctDNA preceded clinical progression. The safety profile of glofitamab monotherapy was manageable, with most adverse events being Grade 1-2. Two patients (11%) experienced Grade ≥ 3 neurotoxicity and recovered after corticosteroid treatment. Two additional patients developed fatal immune effector cell-associated neurotoxicity syndrome following CAR-T consolidation. Glofitamab demonstrates early clinical activity and measurable CNS penetration in R/R PCNSL. Serial CSF ctDNA profiling may aid treatment monitoring, warranting prospective validation.
引用
- Yang A, Dong J, Deng X, et al. Multicenter Real-World Analysis of Glofitamab in Relapsed/Refractory Primary CNS Lymphoma: Clinical Activity, CNS Penetration, and ctDNA Dynamics. Am J Hematol. 2026. PMID: 42035265. doi:10.1002/ajh.70342
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。